Molecular docking analysis of curcumin analogues against kinase domain of ALK5

Ahmed M, Sadek MM, Serrya RA et al (2013) Assessment of new anti-HER2 ligands using combined docking, QM/MM scoring and MD simulation. J Mol Graph Model 40(2):91–98 Akhurst RJ, Derynck R (2001) TGF-Beta Signaling in Cancer–a Double-Edged Sword. Trends Cell Biol 11(11):S44–S51 Allegra Alessandro et al (2017) Anticancer activity of curcumin and its analogues: Preclinical and Clinical Studies. Cancer Invest 35(1):1–22. https://doi.org/10.1080/07357907.2016.1247166 Ammon Hermann, Wahl Martin (1991) Pharmacology of Curcuma Longa. Planta Med 57(1):1–7. https://doi.org/10.1055/s-2006-960004 Boyer S et al (2007) Reaction site mapping of xenobiotic biotransformations. J Chem Inf Model 47(2):583–590. https://doi.org/10.1021/ci600376q Callahan JF et al (2002) Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 45(5):999–1001 Carlsson L et al (2010) Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse. BMC Bioinform 11(1):362. https://doi.org/10.1186/1471-2105-11-362 Clark David E (1999) rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. prediction of blood–brain barrier penetration. J Pharm Sci 88(8):815–821. https://doi.org/10.1021/js980402t DaCosta Byfield S, Major Christopher, Laping Nicholas J, Roberts Anita B (2004) SB-505124 Is a selective inhibitor of transforming growth factor- type i receptors ALK4, ALK5, and ALK7. Mol Pharmacol 65(3):744–752. https://doi.org/10.1124/mol.65.3.744 Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43:3714–3717. https://doi.org/10.1021/jm000942e Gaedeke Jens, Noble Nancy A, Border Wayne A (2004) Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int 66(1):112–120. https://doi.org/10.1111/j.1523-1755.2004.00713.x Gupta, Subash C, Kim Ji Hye, Prasad Sahdeo, Aggarwal Bharat B (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29(3):405–434. https://doi.org/10.1007/s10555-010-9235-2 Gupta Subash C, Patchva Sridevi, Koh Wonil, Aggarwal Bharat B (2012) Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39(3):283–299. https://doi.org/10.1111/j.1440-1681.2011.05648.x Ito Ji et al (2015) PoSSuM v. 2.0: data update and a new function for investigating ligand analogs and target proteins of small-molecule drugs. Nucleic Acids Res 43(D1):D392–D398. https://doi.org/10.1093/nar/gku1144 Jin Cheng Hua et al (2014) Discovery of N -((4-([1,2,4]Triazolo[1,5- a]Pyridin-6-Yl)-5-(6-Methylpyridin-2-Yl)-1 H -Imidazol-2-Yl)methyl)-2-Fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem 57(10):4213–4238. https://doi.org/10.1021/jm500115w Kuttan R, Bhanumathy P, Nirmala K, George MC (1985) Potential anticancer activity of turmeric (Curcuma Longa). Cancer Lett 29(2):197–202 Li H et al (2006) Dihydropyrrolopyrazole transforming growth factor-β Type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-β Type II receptor kinase and mixed lineage kinase-7. J Med Chem 49(6):2138–2142. https://doi.org/10.1021/jm058209g Li Rui et al (2013) Curcumin Inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not smad pathway in renal tubular epithelial cells. PLoS One 8(3):e58848. https://doi.org/10.1371/journal.pone.0058848 Lipinski Christopher A (2004) Lead- and Drug-like Compounds: the rule-of-five evolution. Drug Discov Today Technol 1(4):337–341. https://doi.org/10.1016/j.ddtec.2004.11.007 Liu Z et al (2009) VEGF and inhibitors of TGF Type-I receptor kinase synergistically promote blood-vessel formation by inducing 5-integrin expression. J Cell Sci 122(18):3294–3302. https://doi.org/10.1242/jcs.048942 Lowe DM et al (2011) Chemical name to structure: OPSIN, an open source solution. J Chem Inf Model 51(3):739–753. https://doi.org/10.1021/ci100384d Massagué J (1998) TGF-β signal transduction. Annu Rev Biochem 67(1):753–791. https://doi.org/10.1146/annurev.biochem.67.1.753 Massagué Joan (2008) TGFβ in Cancer. Cell 134(2):215–230. https://doi.org/10.1016/j.cell.2008.07.001 Massagué Joan (2012) TGFβ signalling in context. Nat Rev Mol Cell Biol 13(10):616–630. https://doi.org/10.1038/nrm3434 Massagué J, Blain SW, Lo RS (2000) TGF beta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309. https://doi.org/10.1016/S0092-8674(00)00121-5 Melisi D et al (2008) LY2109761, a novel transforming growth factor receptor type I and Type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7(4):829–840. https://doi.org/10.1158/1535-7163.MCT-07-0337 Morris GM et al (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639–1662. https://doi.org/10.1002/(SICI)1096-987X(19981115)19:14<1639 Negi PS, Jayaprakasha GK, Jagan Mohan Rao L, Sakariah KK (1999) Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 47(10):4297–4300 O’Boyle NM et al (2011) Open Babel: an open chemical toolbox. J Cheminform 3(1):33. https://doi.org/10.1186/1758-2946-3-33 Pence HE, Williams A (2010) ChemSpider: an online chemical information resource. J Chem Educ 87(11):1123–1124. https://doi.org/10.1021/ed100697w Sawyer JS et al (2004) Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. Bioorg Med Chem Lett 14(13):3581–3584. https://doi.org/10.1016/j.bmcl.2004.04.007 Senft Christian et al (2010) The nontoxic natural compound curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer 10(1):491. https://doi.org/10.1186/1471-2407-10-491 Sharma OP (1976) Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 25(15):1811–1812 Shi Yigong, Massagué Joan (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685–700 Singh S, Singh J (1993) Transdermal drug delivery by passive diffusion and iontophoresis: a review. Med Res Rev 13(5):569–621 Son JY et al (2014) EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis. Mol Cancer Ther 13(7):1704–1716. https://doi.org/10.1158/1535-7163.MCT-13-0903 ten Dijke Peter et al (1997) Identification of Smad7, a TGFbeta-Inducible antagonist of TGF-beta signalling. Nature 389(6651):631–635. https://doi.org/10.1038/39369 Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. NIH Public Access. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334 Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95(6):779–791 Veber Daniel F et al (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45(12):2615–2623 Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127–134 Wrana Jeffrey L, Attisano Liliana, Wieser Rotraud, Ventura Francesc, Massagué Joan (1994) Mechanism of activation of the TGF-β receptor. Nature 370(6488):341–347. https://doi.org/10.1038/370341a0 Xu Jian, Lamouille Samy, Derynck Rik (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Res 19(2):156–172. https://doi.org/10.1038/cr.2009.5 Yamashita S et al (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci Off J Eur Fed For Pharm Sci 10(3):195–204